



efan  
Docket No.: PF107D6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Hastings et al.

Application No.: 10/726,645

Confirmation No.: 6181

Filed: December 4, 2003

Art Unit: 1644

For: Human Osteoclast Derived Cathepsin

Examiner: M. Belyavskyi

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:                   /

Applicants submit herewith a Statement Under 37 C.F.R. § 3.73, Revocation of Prior Powers of Attorney or Authorizations of Agent, and Power of Attorney or Authorization of Agent ("Power of Attorney") (in 2 counterparts), signed by both assignees in the present application.

Applicants respectfully request entry of the Power of Attorney into the official application records.

Dated: April 20, 2005

Respectfully submitted,

By   
Doyle A. Siever

Registration No.: 47,088  
HUMAN GENOME SCIENCES, INC.  
Intellectual Property Dept.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(301) 354-3932



**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Hastings, et al.

Attorney Docket No.: PF107D6

Application No.: 10/726,645; Conf. #6181      Art Unit: 1644

Filed: December 4, 2003

Examiner: Belyavskiy, Michail A.

Title: Human Osteoclast-Derived Cathepsin

**STATEMENT UNDER 37 C.F.R. § 3.73, REVOCATION OF PRIOR  
POWERS OF ATTORNEY OR AUTHORIZATIONS OF AGENT,  
AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Statement Under 37 C.F.R. § 3.73**

Human Genome Sciences, Inc. ("HGS"), organized and existing under the laws of the State of Delaware, having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850, states that it is the assignee of record of the fifty percent (one-half) of the right, title and interest for the above-identified application by virtue of an assignment from inventor Gregg A. Hastings, recorded in the U.S. Patent and Trademark Office on June 23, 1994, at Reel 7105, Frame 0912, and by virtue of an assignment from inventors Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, and Lisa M. Fitzgerald to The Institute for Genomic Research (TIGR), and from TIGR to HGS, recorded in the U.S. Patent and Trademark Office on June 23, 1994 at Reel 7106, Frame 0436. These assignments were directed to the great grand-parent application (U.S. Application No. 08/208,007, filed March 8, 1994, now U.S. Patent No. 5,501,969, issued March 26, 1996) that matured into the above-identified patent, and all continuation and divisional applications thereof.

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of HGS. The undersigned has reviewed all the documents in the chain of title of the above-captioned application, and, to the best of the undersigned's knowledge and belief, HGS has title in the application as described above.

**Revocation of Prior Powers of Attorney or Authorizations of Agent**

HGS hereby revokes all previous powers of attorney or authorizations of agent given in the above-captioned application.

**Power of Attorney or Authorization of Agent**

HGS hereby appoints the Practitioners at **Customer Number 22195** as its attorneys or agents with full power of substitution, association, and revocation to prosecute the above-captioned application, including any continuations or divisionals thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-captioned application to the above-mentioned Customer Number, namely **22195**.

On behalf of Human Genome Sciences, Inc.:

For: Human Genome Sciences, Inc.

Signature: 

Name: James H. Davis

Title: Executive Vice President and General Counsel

Date: Feb 18, 2005



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Hastings, et al.

Attorney Docket No.: PF107D6

Application No.: 10/726,645; Conf. #6181      Art Unit: 1644

Filed: December 4, 2003

Examiner: Belyavskyi, Michail A.

Title: Human Osteoclast-Derived Cathepsin

**STATEMENT UNDER 37 C.F.R. § 3.73, REVOCATION OF PRIOR  
POWERS OF ATTORNEY OR AUTHORIZATIONS OF AGENT,  
AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Statement Under 37 C.F.R. § 3.73**

SmithKline Beecham Corporation ("SKB"), organized and existing under the laws of the Commonwealth of Pennsylvania, having its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19103, states that it is the assignee of record of the fifty percent (one-half) of the right, title and interest for the above-identified application by virtue of an assignment from inventors Maxine Gowan and Fred H. Drake, recorded in the U.S. Patent and Trademark Office on June 23, 1994, at Reel 7105, Frame 0915. This assignment was directed to the great grand-parent application (U.S. Application No. 08/208,007, filed March 8, 1994, now U.S. Patent No. 5,501,969, issued March 26, 1996) that matured into the above-identified patent, and all continuation and divisional applications thereof.

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of SKB. The undersigned has reviewed all the documents in the chain of title of the above-captioned application, and, to the best of the undersigned's knowledge and belief, SKB has title in the application as described above.

**Revocation of Prior Powers of Attorney or Authorizations of Agent**

SKB hereby revokes all previous powers of attorney or authorizations of agent given in the above-captioned application.

**Power of Attorney or Authorization of Agent**

SKB hereby appoints the Practitioners at **Customer Number 22195** as its attorneys or agents with full power of substitution, association, and revocation to prosecute the above-captioned application, including any continuations or divisionals thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-captioned application to the above-mentioned Customer Number, namely **22195**.

On behalf of SmithKline Beecham Corporation:

For: SmithKline Beecham Corporation

Signature: \_\_\_\_\_

Name: Stephen Venetianer

Title: Vice President, Pharmaceuticals

Date: 30 March 2005